Dicerna Pharmaceuticals, Inc.
DRNA
DRNA was delisted on the 27th of December, 2021.
169 hedge funds and large institutions have $1.27B invested in Dicerna Pharmaceuticals, Inc. in 2019 Q4 according to their latest regulatory filings, with 67 funds opening new positions, 50 increasing their positions, 40 reducing their positions, and 9 closing their positions.
644% more first-time investments, than exits
New positions opened: 67 | Existing positions closed: 9
52% more capital invested
Capital invested by funds: $840M → $1.27B (+$434M)
51% more funds holding
Funds holding: 112 → 169 (+57)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
25% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 40
25% less call options, than puts
Call options by funds: $1.98M | Put options by funds: $2.65M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$40.3M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$25.4M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$20M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$16.6M |
| 5 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$12.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$65.4M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$43.3M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$35.3M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
-$17.6M |
| 5 |
BM
Bridger Management
New York
|
-$13.6M |
DRNA Hedge Fund Activity: Q4 2019 in Review
169 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Dicerna Pharmaceuticals, Inc. (DRNA) for Q4 2019, worth a combined $1.27B — up 52% from $840M a quarter earlier.
Buyers outnumbered sellers: 67 funds opened new DRNA positions and 9 closed out — a net gain of 58 holders — while 50 added to existing stakes and 40 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $40.3M. The largest seller was Bain Capital Life Sciences Investors, cutting an estimated $65.4M.
- 169 institutional investors held Dicerna Pharmaceuticals, Inc. (DRNA) as of Q4 2019, up from 112 in Q3 2019.
- Funds reported $1.27B of Dicerna Pharmaceuticals, Inc. stock for Q4 2019, up 52% quarter-over-quarter.
- 67 funds opened new Dicerna Pharmaceuticals, Inc. positions in Q4 2019 and 9 closed out, a net change of +58 holders.
- The largest Dicerna Pharmaceuticals, Inc. buyer in Q4 2019 was T. Rowe Price Associates, an estimated $40.3M added.
- The largest Dicerna Pharmaceuticals, Inc. seller in Q4 2019 was Bain Capital Life Sciences Investors, an estimated $65.4M sold.
Based on aggregated 13F filings for Q4 2019.